Replication and Genome Stability Group

Publications

Cyclin Dependent Kinase 2 inhibitors in cancer therapy: an update
Tadesse, S.; Caldon, E. C.; Tilley, W.; Wang, S.
JOURNAL OF MEDICINAL CHEMISTRY 62(9):4233-4251, 2019
The proliferative and apoptotic landscape of basal-like breast cancer
Alexandrou, S.; George, S. M.; Ormandy, C. J.; Lim, E.; Oakes, S. R.; Caldon, C. E.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20(3):667, 2019
Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer
Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C. E.
ENDOCRINE-RELATED CANCER 26:R15-R30, 2019
Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon, C.E.; Sergio, C.M.; Kang, J.; Muthukaruppan, A.; Boersma, M.; Stone, A.; Barraclough, J. Lee, C.S.L.; Black, M.A.; Miller, L.D.; Gee, J.M.; Nicholson, R.I.; Sutherland, R.L.; Print, C.G.; Musgrove, E.A.
MOLECULAR CANCER THERAPEUTICS 11(7):1488-99, 2012
Label free, quantitative single-cell fate tracking of time-lapse movies
Caldon, C. E.; Burgess, A.
MethodsX 6:2468-2475, 2019
Estrogen signaling and the DNA damage response in hormone dependent breast cancers
Caldon, C. E.;
Frontiers in Oncology 4:106, 2014
Cyclin E2 promotes whole genome doubling in breast cancer
Lee, C.; Fernandez, K. J.; Alexandrou, S.; Sergio, C. M.; Deng, N.; Rogers, S.; Burgess, A.; Caldon, C. E.
Cancers 12(8):2268, 2020
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes
Aziz, D.; Etemadmoghadam, D.; Caldon, C. E.; Au-Yeung, G.; Deng, N.; Hutchinson, R.; Bowtell, D.; Waring, P.
GYNECOLOGIC ONCOLOGY 151(2):327-336, 2018
Editorial: Proceedings From ACCM19: Cell Cycle, DNA Damage Response and Telomeres
Burgess, A.; Caldon, C. E.
Frontiers in Cell and Developmental Biology 8:805, 2020
Friends and foes: Our evolving understanding of the link between Fbxw7 and p53 in cancer
Caldon, C.E.
NEOPLASIA 22(11):659-660, 2020
Cell cycle proteins in epithelial cell differentiation: implications for breast cancer
Caldon, C.E., Sutherland, R.L.; Musgrove, E.A.
CELL CYCLE 9(10):1918-1928, 2010
Estrogen regulation of cyclin E2 requires cyclin D1, but not c-Myc
Caldon, C.E.; Sergio, C.M.; Schutte, J.; Boersma, M.N.; Sutherland, R.L.; Carroll, J.S.; Musgrove, E.A.
MOLECULAR AND CELLULAR BIOLOGY 29(17):4623-4639, 2009
Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1
Caldon, C.E.; Sergio, C.M.; Burgess, A.; Deans, A.J.; Sutherland, R.L.; Musgrove, E.A.;
CELL CYCLE 12(4):606-617, 2013
Cdk2 regulates metastasis suppressor BRMS1
Caldon, C. E.;
CELL CYCLE 15(6):779-80, 2016
Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells
Caldon, C. E.; Sergio, C.M.; Sutherland, R.L.; Musgrove, E.A.;
CELL CYCLE 12(4):596-605, 2013
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S.; Anshabo, A. T.; Portman, N.; Lim, E.; Tilley, W.; Caldon, C. E.; Wang, S.
DRUG DISCOVERY TODAY 25(2):406-413, 2020
Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer
Caldon, C. E.; Musgrove, E.A.
Cell Division 5:2, 2010